Open Access. Powered by Scholars. Published by Universities.®

Pharmacy and Pharmaceutical Sciences Commons™

Open Access. Powered by Scholars. Published by Universities.®

2024

Discipline
Institution
Keyword
Publication
Publication Type
File Type

Articles 721 - 729 of 729

Full-Text Articles in Pharmacy and Pharmaceutical Sciences

Unpatenting Product Hops, Michael S. Sinha Jan 2024

Unpatenting Product Hops, Michael S. Sinha

All Faculty Scholarship

On July 9, 2021, President Joseph R. Biden signed Executive Order 14036 (“Promoting Competition in the American Economy”), which directed the U.S. Food and Drug Administration (FDA) and the U.S. Patent and Trademark Office (USPTO) to collaborate on new approaches to increasing competition and lowering prices in the pharmaceutical marketplace. In response, the USPTO outlined several new initiatives, among them an intent to improve the robustness and reliability of issued patents.

A major impetus for the Executive Order was the pervasive nature of pharmaceutical product hopping, which occurs when manufacturers introduce new follow-on versions of lucrative pharmaceutical products to the …

Go to article

Ai Renaissance: Pharmaceuticals And Diagnostic Medicine, Ty J. Feeney, Michael S. Sinha Jan 2024

Ai Renaissance: Pharmaceuticals And Diagnostic Medicine, Ty J. Feeney, Michael S. Sinha

All Faculty Scholarship

The explosive growth of Artificial Intelligence (AI) in the modern era has led to significant advancements in the world of medicine. In drug discovery, AI technology is used to classify proteins as drug targets or non-targets for specific diseases, more accurately interpret and describe pharmacology in a quantitative fashion, and predict protein structures based on only a protein sequence for input. AI methods are used in drug development to generate predictive models for drug screening purposes, refine and modify candidate structures of drugs to optimize compounds, and predict a drug’s physiochemical properties, bioactivity, and toxicity. For medical devices, the advancement …

Go to article

Breast Tissue As A Local Drug Reservoir For Anticancer Therapy In Breast Cancer, Saniia Shchinar Jan 2024

Breast Tissue As A Local Drug Reservoir For Anticancer Therapy In Breast Cancer, Saniia Shchinar

Electronic Theses and Dissertations

Breast cancer, particularly the estrogen receptor-positive (ER+) subtype, remains a formidable challenge in oncology. Traditional oral therapies for ER-positive breast cancer, such as selective estrogen receptor modulators (SERMs) like Tamoxifen (TAM) and Toremifene (TOR), often encounter issues related to limited bioavailability, metabolic complications, and significant systemic side effects. These side effects include the risk of blood clots, hot flashes, vaginal dryness, menstrual cycle disruptions, and uterus cancer, which can hinder long-term adherence to preventive therapy. The exploration of local drug delivery into breast tissue presents a promising alternative to tackle these challenges. In this study, we explored the feasibility of …

Go to article

Delivery Of Gemcitabine, Stearoyl Gemcitabine And Paclitaxel Through Plga Nanoparticles And Its Effect On The Desmoplasia Of Pancreatic Cancer Spheroids, Rishabh Bahl Jan 2024

Delivery Of Gemcitabine, Stearoyl Gemcitabine And Paclitaxel Through Plga Nanoparticles And Its Effect On The Desmoplasia Of Pancreatic Cancer Spheroids, Rishabh Bahl

Electronic Theses and Dissertations

Pancreatic cancer is one of the deadliest cancers to treat. The primary cause for the drug resistance is the dense extracellular matrix (ECM) that surrounds the tumor and restricts blood supply. Gemcitabine (GEM) and paclitaxel (PTX) are drugs that are clinically used in the treatment of pancreatic cancer. GEM, however, is rapidly metabolized by cytidine deaminase (CDA) and eliminated from the body, and paclitaxel is a substrate for P- glycoprotein (P-gp) efflux receptors. Drug delivery using nanoparticles has been reported to help improve drug half-lives and bypass efflux receptors. This thesis aims to encapsulate PTX in PLGA nanoparticles (PTX-NP) and …

Go to article

Enhancing Organisational Performance Through Patient-Focused Learning Excellence In The Biopharmaceutical Industry, Lori Richter Jan 2024

Enhancing Organisational Performance Through Patient-Focused Learning Excellence In The Biopharmaceutical Industry, Lori Richter

Dissertations

Drug shortages, quality defects and challenges regarding innovation within the biopharmaceutical industry pose significant risks to patient safety and organisational performance. These problems persist despite the many scientific, technological and economic advances over the past several years in a well-funded, high-revenue industry operated by highly qualified personnel. Evidence suggests that the industry has yet to fully realise the potential for building organisational capabilities to enable learning from mistakes to enhance performance outcomes. This research study explored how biopharmaceutical companies can learn from their mistakes and embrace a culture of learning in order to reduce quality defects and drug shortages by …

Go to article

4d Epr Oximetry Imaging For 4d Bioprinting And Tissue Engineering, Sajad Sarvari Jan 2024

4d Epr Oximetry Imaging For 4d Bioprinting And Tissue Engineering, Sajad Sarvari

Graduate Theses, Dissertations, and Problem Reports (ETD)

Bioprinting, akin to 3D printing, employs cell-laden hydrogels such as GelMA (Gelatine Methacrylate) and Alginate instead of plastic or resin to create biological structures. The printing process followed by subsequent tissue maturation is known as 4D bioprinting, where the fourth dimension is time. Ensuring adequate and consistent oxygen, O2, supply within 3D bioprint volume over the entire maturation period process is crucial, as even transient hypoxia can impact cellular behavior and phenotypes. However, printing of fully developed vasculature remains an unresolved technical challenge. Several approaches to chemically (peroxides) or biologically (photosynthesis) generate oxygen during bioprint maturation have been proposed. However, …

Go to article

Intervention To Reduce Tobacco Use Among Prostate Cancer Patient And Informal Caregiver Dyads, Trupti Dhumal Jan 2024

Intervention To Reduce Tobacco Use Among Prostate Cancer Patient And Informal Caregiver Dyads, Trupti Dhumal

Graduate Theses, Dissertations, and Problem Reports (ETD)

Prostate cancer is the leading cancer in men. Continued tobacco use after prostate cancer diagnosis may affect a patient’s treatment outcomes, quality of life, and mortality. Despite the potential negative outcomes, 10-20% of prostate cancer patients continue to use tobacco after their cancer diagnosis. Considering risks associated with continued tobacco use, there is a lack of evidence-based tobacco cessation strategies to address tobacco cessation specifically in prostate cancer. Given the increasing prevalence of prostate cancer, the ongoing difficulty in tobacco cessation, and the limited evidence-based tobacco cessation interventions in the literature, it is important to prioritize reducing tobacco use in …

Go to article

Dual Activity Of Aromatic And Heterocyclic Compounds As Anti-Inflammatory And Anticancer Promising Agents, Samar Said Fatahala, Rania Helmy Abd El-Hameed, Mosaad Sayed Mohamed, Neama Abdallah Abd El-Tawab Jan 2024

Dual Activity Of Aromatic And Heterocyclic Compounds As Anti-Inflammatory And Anticancer Promising Agents, Samar Said Fatahala, Rania Helmy Abd El-Hameed, Mosaad Sayed Mohamed, Neama Abdallah Abd El-Tawab

Trends in advanced sciences and technology

As the second leading cause of mortality worldwide, cancer poses a severe threat to human health. Chronic inflammation has recently been linked to an increased risk for a number of malignancies, suggesting that reducing inflammation could be a useful approach to both cancer prevention and treatment. This review delves into the connection between inflammation and cancer and outlines the current use of anti-inflammatory drugs as potentially effective cancer prevention and therapy strategies. we herein describe the main relation and the mechanisms underlying the anti-cancer outcomes of anti-inflammatory agents; namely Non-Steroidal Anti-inflammatory Drugs (NSAIDs), COX-2 inhibitors, LOX-inhibitors, Toll- inhibitors, and antioxidant …

Go to article

Sharksrx Newsletter Spring 2024, Nova Southeastern University Jan 2024

Sharksrx Newsletter Spring 2024, Nova Southeastern University

NSU Sharks Rx

No abstract provided.

Go to article

First Prev